David Lebwohl Receives Stock Award at Intellia Therapeutics Inc (NTLA) — SEC Form 4, Mar 03, 2026

SEC Form 4 · No Market Transaction

Stock Award

Compensation grant — no market purchase or sale.

Reporting Owner

David Lebwohl

EVP

TXN 2026-03-01 · FILED 2026-03-03

Equity Position 131K sh 121,249 → 131,192

Equity Change +8.2% shares held after vs before

Filing Lag 2 business days within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Intellia Therapeutics Inc

NTLA CIK 0001652130

Reporting Owner

Name	Relationship
David Lebwohl CIK 0001810882	EVP

David Lebwohl at Intellia Therapeutics Inc Full insider history

Bought (12 mo) —

Sold (12 mo) $109,627

More from this insider at Intellia Therapeutics Inc

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common StockF1	2026-03-01	A - Award/Grant	9,943 A	$0.00	—	131,192	Direct

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Stock Option (right to buy)F2	$13.78	2026-03-01	A - Award/Grant	14,204 A	$0.00	2036-02-29	14,204 Common Stock	Direct

Footnotes (2)

F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Show more
F2: This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Show more

Institutional Holders

Largest by reported value

5%+ Holders · 13D/G 5 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Intellia Therapeutics Inc

GET /v1/forms/4/0001193125-26-088258 API docs